Abemaciclib mesylate (LY2835219)

For research use only. Not for use in humans.

目录号:S7158 中文名称:甲磺酸阿贝西尼

Abemaciclib mesylate (LY2835219) Chemical Structure

CAS No. 1231930-82-7

Abemaciclib (LY2835219)是一种有效的,选择性CDK4CDK6抑制剂,无细胞试验中IC50分别为2 nM和10 nM。Phase 3。

规格 价格 库存 购买数量  
10mM (1mL in DMSO) RMB 4644.52 现货
RMB 2203.44 现货
RMB 3333.88 现货
RMB 6544.35 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck生产的Abemaciclib mesylate (LY2835219)发表文献41篇:

产品安全说明书

CDK抑制剂选择性比较

生物活性

产品描述 Abemaciclib (LY2835219)是一种有效的,选择性CDK4CDK6抑制剂,无细胞试验中IC50分别为2 nM和10 nM。Phase 3。
靶点
CDK4 [1]
(Cell-free assay)
CDK6 [1]
(Cell-free assay)
2 nM 10 nM
体外研究

LY2835219是一种口服有效的细胞周期蛋白依赖性激酶(CDK)抑制剂,靶向作用于CDK4(cyclin D1)和CDK6(cyclin D3)细胞周期通路,具有潜在的抗肿瘤活性。LY2835219特异性抑制CDK4和6,从而在早G1期抑制视网膜母细胞瘤(Rb)蛋白磷酸化。抑制Rb磷酸化,防止CDK-介导的G1-S期转换,从而使细胞周期停滞在G1期,抑制DNA合成,且抑制癌细胞生长。某些类型的癌症中丝/苏氨酸激酶CDK4/6的过表达,导致细胞周期调节失控。[1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
human COLO205 cells NIf0eFhHfW6ldHnvckBie3OjeR?= NWm2SIdSOjRiaB?= M4DBNWlvcGmkaYTpc44hd2ZiQ1TLOE83KGmwIHj1cYFvKEORTF:yNFUh[2WubIOgZZN{\XO|ZXSgZZMhdWG6aX31cUBk\WyuIHP5Z4xmKGG{cnXzeEBifCCJMTDwbIF{\SCjZoTldkAzPCCqcoOgZpkheHKxcHnkbZVuKGmxZHnk[UB{fGGrbnnu[{1j[XOnZDDmcI94KGO7dH;t[ZRzcWNiYX7hcJl{cXN? NFjZRos9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkGxOVU4OSd-Mk[xNVU2PzF:L3G+
human COLO205 cells MkTySpVv[3Srb36gZZN{[Xl? MoH1NlQhcA>? NVSyNIk5UW6qaXLpeIlwdiCxZjDDSGs1NzZiaX6gbJVu[W5iQ1;MU|IxPSClZXzsd{Bie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJHJjKHCqb4PwbI9zgWyjdHnvckBi\nSncjCyOEBpenNiYomgdJJweGmmaYXtJIlw\GmmZTDzeIFqdmmwZz3iZZNm\CCuYYPldk1{[2Gwbnnu[{BndHWxcnXzZ4Vv[2VibXnjdo9xdGG2ZTDjfZRwdWW2cnnjJIFv[Wy7c3nz NEPqWJo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkGxOVU4OSd-Mk[xNVU2PzF:L3G+
insect cells  M2S2SmZ2dmO2aX;uJIF{e2G7 M{HxU|UxKG2rboO= MXPJcohq[mm2aX;uJI9nKGi3bXHuJGNFUzRxY4njcIlvKERzIHX4dJJme3OnZDDpckBqdnOnY4SgZ4VtdHNiYYPz[ZN{\WRiYYOgdIhwe3Cqb4L5cIF1cW:wIH;mJGNVWkZiYX\0[ZIhPTBibXnud{BjgSCvaXPyc5Bt[XSnIIPjbY51cWyuYYTpc44h[2:3boTldkwhUUN3ME2yJI5O MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjFzNUW3NUc,OjZzMUW1O|E9N2F-
insect cells  NF3NUHZHfW6ldHnvckBie3OjeR?= Mni5OVAhdWmwcx?= NVjEbJNzS2:vcHX0bZRqfmViaX7obYJqfGmxbjDv[kBpfW2jbjDDSGs1N2O7Y3zpckBFOSCneIDy[ZN{\WRiaX6gbY5{\WO2IHPlcIx{KGG|c3Xzd4VlKGG|IIDoc5NxcG:{eXzheIlwdiCxZjDDWHJHKGGodHXyJFUxKG2rboOgZpkhVWmlaHHlcIl{NU2nboTlckBxdG:2IHHuZYx6e2m|IHnuJJBz\XOnbnPlJI9nKEGWUDygT4k:OC54IH7N NUPQZ4RkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[xNVU2PzFpPkK2NVE2PTdzPD;hQi=>
HCT116 NUTHWolQSW62aYDyc4xq\mW{YYTpeoUh[XO|YYm= NVi3OZN1PzJiaILz MkHuTWM2OCB;IECuOVQh|ryP NGj3TlQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9|MEG2OVM1OSd-M{CxOlU{PDF:L3G+
MCF7 NEj0N5RCdnSrcILvcIln\XKjdHn2[UBie3OjeR?= M{fhcFczKGi{cx?= NG[zR2pKSzVyIE2gNE44OSEQvF2= NX;TN|BJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CxOlU{PDFpPkOwNVY2OzRzPD;hQi=>
PANC1 M2TwRWFvfGmycn;sbYZmemG2aY\lJIF{e2G7 NYnyWIdRPzJiaILz M2jqSmlEPTBiPTC1Mlk1KM7:TR?= NVmxT5JKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CxOlU{PDFpPkOwNVY2OzRzPD;hQi=>
Sf9 M3jjdGZ2dmO2aX;uJIF{e2G7 NIXNOWtKdmirYnn0bY9vKG:oIFPET|EwS3mlbHnuJGIhMHWwa37ve44hd3KrZ3nuLUBmgHC{ZYPz[YQhcW5iYnHjeYxwfmm{YXygbY5n\WO2ZXSgbY5{\WO2IGPmPUBk\WyuczD1d4lv\yCqaYP0c45mKEhzIHHzJJN2[nO2cnH0[UBqdiCycnXz[Y5k\SCxZjDb[4FudWFvM{PQYWFVWCxiSVO1NEA:KDBwM{exJO69VS5? M37FNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4N{SxPFU{Lz5{Nke0NVg2OzxxYU6=
Sf9 MXPGeY5kfGmxbjDhd5NigQ>? MUK5NEBucW6| M3;JS2lvcGmkaYTpc44hd2ZicnXjc41jcW6jboSgbJVu[W5iTj30[ZJucW6jbDDHV3QufGGpZ3XkJGNFUzRiKESgeI8hOzB|IILld4llfWW|KT;jfYNtcW5iREGgLFQhfG9iMkm1JJJme2mmdXXzLUBmgHC{ZYPz[YQhcW5ic3[5JINmdGy|IIXzbY5oKENvdHXycYlv[WxicnX0bY5w[myjc4TvcYEh\nKjZ33lcpQh[XNic4Xid5Rz[XSnIHHmeIVzKDlyIH3pcpMh[nliW3fhcY1iNTN|UG3BWHAh[mG|ZXSgcYlkem:kZYThJJNkcW62aXzsZZRqd25iY3;1cpRqdixiS3mgQUAxNjByMjFOwG0v M4nhV|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5MUexNFM3Lz5{N{G3NVA{PjxxYU6=
Sf9 NYC2N|JSTnWwY4Tpc44h[XO|YYm= NYC0c5FWQTBibXnudy=> NIL0OoFKdmirYnn0bY9vKG:oIILlZ49u[mmwYX70JIZ2dGxibHXu[5RpKGi3bXHuJG4ufGW{bXnuZYwhT1OWLYTh[4dm\CCFRFu2JEgyKHSxIEOyOkBz\XOrZIXld{kw[3mlbHnuJGQyKCh2IITvJFI6PSC{ZYPp[JVmeyliZYjwdoV{e2WmIHnuJJNnQSClZXzsd{B2e2mwZzDDMZRmem2rbnHsJJJmfGmwb3LsZZN1d22jIH\yZYdu\W62IHHzJJN2[nO2cnH0[UBi\nSncjC5NEBucW6|IHL5JHto[W2vYT2zN3BeSVSSIHLhd4VlKG2rY4LvZoV1[SC|Y3nueIltdGFuIFvpJF0hOC5yMTFOwG0v MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzF5MUCzOkc,OjdzN{GwN|Y9N2F-
Sf21 MYjGeY5kfGmxbjDhd5NigQ>? NED3OXNKdmirYnn0bY9vKG:oIILlZ49u[mmwYX70JIh2dWGwIH\1cIwhdGWwZ4ToJGMufGW{bXnuZYwhUGm|Nj30ZYdo\WRiQ1TLO{9kgWOuaX6gTE9PNXSncn3pcoFtKEeVVD30ZYdo\WRiTVHUNUBmgHC{ZYPz[YQhcW5iYnHjeYxwfmm{dYOgbY5n\WO2ZXSgV4YzOSCrboPlZ5Qh[2WubIOgeZNqdmdiY3TrO{B{fWK|dILheIUheGWydHnk[UwhU2liPTCzMlkyKM7:TT6= NHLYbFM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{G3NVA{Pid-MkexO|ExOzZ:L3G+
COLO205 M2nKbGFvfGmycn;sbYZmemG2aY\lJIF{e2G7 MXW5OkBpenN? NUDGZ5BFSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDDU2xQOjB3IHPlcIx{KGGodHXyJFk3KGi{czDifUBES0tvODDhd5NigSxiSVO1NEA:KDBwNE[g{txONg>? NYO3UmI6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkmwO|QzPTRpPkK5NFc1OjV2PD;hQi=>
U87MG MXHBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>? MoniO|IhcHK| M2TnemFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iVUi3UWch[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IFTBVGkhe3SjaX7pcoch[mG|ZXSgZZN{[XluIFnDOVAhRSByLkC0PFEh|ryPLh?= MlG3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl{NEe4OVcoRjJ7MkS3PFU4RC:jPh?=
Sf9 MnrYSpVv[3Srb36gZZN{[Xl? MYPJcohq[mm2aX;uJI9nKHKnY3;tZolv[W62IHj1cYFvKE5vdHXycYlv[WxiR2PUMZRi\2enZDDDSGs1KCiVNDD0c{BGOzB|IILld4llfWW|KT;DfYNtcW5iREGgLHE1KHSxIFmyPVUhemW|aXT1[ZMqKGW6cILld5Nm\CCrbjDz[lkh[2WubIOgeZNqdmdiUnKgdJJwfGWrbjCoO|c{KHSxIEmyPEBz\XOrZIXld{kh[XNic4Xid5Rz[XSnIHnuJJBz\XOnbnPlJI9nKFt|M2DdMWFVWCCkeTDzZ4lvfGmubHH0bY9vKGOxdX70bY5oKG2ndHjv[EwhUUN3MDC9JFAvODB{IN88UU4> M4DOeFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEK5PFMzLz5{OUSyPVg{OjxxYU6=
Sf9 MYDGeY5kfGmxbjDhd5NigQ>? NH;FPHA6OCCvaX7z Ml7sTY5pcWKrdHnvckBw\iC{ZXPvcYJqdmGwdDDoeY1idiCodXzsJIxmdme2aDDDSGs3KGW6cILld5Nm\CCrbjDiZYN2dG:4aYL1d{Bqdm[nY4Tl[EBU\jliaX7z[YN1KGOnbHzzJJV{cW6pIHjpd5RwdmViSEGgd5Vje3S{YYTlJIFnfGW{IEmwJI1qdnNiYomgRWRRNUeubzDhd5NigSxiSVO1NEA:KDBwMEC3PEDPxE1w MmGyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2Mkm4N|IoRjJ7NEK5PFMzRC:jPh?=
Sf9 NYfCfJlFTnWwY4Tpc44h[XO|YYm= MVHJcohq[mm2aX;uJI9nKHKnY3;tZolv[W62IHj1cYFvKE5vdHXycYlv[WxiR2PUMZRi\2enZDDDSGs1KCiPMTD0c{BCOzJ4IILld4llfWW|KT;DfYNtcW5iREGgLHE1KHSxIFmyPVUhemW|aXT1[ZMqKGW6cILld5Nm\CCrbjDz[lkh[2WubIOgeZNqdmdiUnKgdJJwfGWrbjCoO|c{KHSxIEmyPEBz\XOrZIXld{kh[XNic4Xid5Rz[XSnIHnuJJBz\XOnbnPlJI9nKFt|M2DdMWFVWCCkeTDzZ4lvfGmubHH0bY9vKGOxdX70bY5oKG2ndHjv[EwhUUN3MDC9JFAvODFizszNMi=> MoXSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2Mkm4N|IoRjJ7NEK5PFMzRC:jPh?=
Sf9 MkTqSpVv[3Srb36gZZN{[Xl? MUi5NEBucW6| MoPNTY5pcWKrdHnvckBw\iC{ZXPvcYJqdmGwdDDoeY1idiCodXzsJIxmdme2aDDDSGsyN0O7Y3zpckBFOyCneIDy[ZN{\WRiaX6gZoFkfWyxdnnyeZMhcW6oZXP0[YQhW2Z7IHnud4VkfCClZXzsd{B2e2mwZzDobZN1d26nIFixJJN2[nO2cnH0[UBi\nSncjC5NEBucW6|IHL5JGFFWC2JbH:gZZN{[XluIFnDOVAhRSByLkC1OkDPxE1w NFXkWGs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSyPVg{Oid-Mkm0Nlk5OzJ:L3G+
MDA-MB-231 NUnVNGhuSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbh?= MnjEO|IhcHK| NGC5e5FCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3ERU1OSi1{M{GgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KESDUFmgd5RicW6rbnegZoF{\WRiYYPzZZktKEmFNUCgQUAxNjF7MTFOwG0v NWHQN5hbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0Nlk5OzJpPkK5OFI6QDN{PD;hQi=>
COLO205 NVLkellnSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbh?= MoXpPVYhcHK| MnTuRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCFT1zPNlA2KGOnbHzzJIFnfGW{IEm2JIhzeyCkeTDDR2s5KGG|c3H5MEBKSzVyIE2gNE4zOTdizszNMi=> NIjuXJI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUS1PVI4PCd-Mkm0OVkzPzR:L3G+
MDA-MB-468 NUm0T2Q4SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbh?= NXSw[GdSQTZiaILz MXLBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE2GQT3NRk01PjhiY3XscJMh[W[2ZYKgPVYhcHK|IHL5JGNEUzhiYYPzZZktKEmFNUCgQUA1NjhyODFOwG0v NYD2RXBFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0OVkzPzRpPkK5OFU6Ojd2PD;hQi=>
COLO205 M33uTWlvcGmkaYTpc44hd2ZiQ1TLOEBqdiCqdX3hci=> MoDBNE4yKHSxIEGwJJVO MmnVNlQhcHK| MlX4TY5pcWKrdHnvckBw\iCFRFu0JIlvKGi3bXHuJGNQVE9{MEWgZ4VtdHNiYYPz[ZN{\WRiYYOgdoVlfWO2aX;uJIlvKHSxdHHsJHJjKHC{b4TlbY4hdGW4ZXygZZQhOC5zIITvJFExKHWPIHHmeIVzKDJ2IHjyd{BjgSCrbX31co9jdG:2dHnu[{Bu\XSqb3S= NFj2Nnc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUS1PVI4PCd-Mkm0OVkzPzR:L3G+
COLO205 NIDiO|NE\WyuIHP5Z4xmKGG|c3H5 M4nQNZVxKHSxIEGwJJVO NUH6d4VNOjRiaILz NHHicY5E\WyuIHP5Z4xmKGG{cnXzeEBqdiCqdX3hckBEV0yRMkC1JINmdGy|IHHzd4V{e2WmIHHzJIFk[3WvdXzheIlwdiCjdDDHNk9OKHCqYYPlJJVxKHSxIEGwJJVOKGGodHXyJFI1KGi{czDifUBxem:yaXTpeY0hcW:maXTlJJN1[WmwaX7nJIJie2WmIF\BR3Mh[W6jbInzbZM> NFrWRXo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUS1PVI4PCd-Mkm0OVkzPzR:L3G+

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p-Rb(S780) / Rb / p21; 

PubMed: 26909611     


Effects of LY2835219 on RB phosphorylation and p21 expression were evaluated by immunoblotting at indicated concentrations (A)

p-ERK / ERK / p-Akt / Akt / p-mTOR(S2448) / mTOR; 

PubMed: 26909611     


Effects of LY2835219 on RB phosphorylation and p21 expression were evaluated by immunoblotting at indicated time points (B).

pRb(S795) / E2F1 / Cyclin A2 / Cyclin E2; 

PubMed: 27748766     


(c) MCF-7 and MR cells were treated with 100 nm LY2835219 and collected at indicated times. Immunoblots were performed with the indicated antibodies. (d) MCF-7 and MR cells were treated with increasing concentrations of LY2835219 and harvested after 24 h; lysates were then subjected to immunoblotting.

26909611 27748766
Growth inhibition assay
Cell viability; 

PubMed: 26909611     


Cell viability of OSC-19, FaDu, and YD-10B cells treated with LY2835219 at indicated concentrations. Data are representative of three independent experiments: mean ± SEM.

26909611
体内研究 LY2835219-MsOH处理脑的剂量百分比为0.5–3.9%。LY2835219-MsOH处理皮下和颅内胶质瘤模型(U87MG),抑制肿瘤生长,这种作用存在剂量依赖性,不管是单独处理,还是与Temozolomide联用。[1]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

溶解度 (25°C)

体外 Water 100 mg/mL (165.92 mM)
DMSO 83 mg/mL (137.71 mM)
Ethanol '''24 mg/mL
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
water
100mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 602.7
化学式

C27H32F2N8.CH4O3S

CAS号 1231930-82-7
储存条件 粉状
溶于溶剂
别名 N/A

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % ddH2O
计算重置

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04627064 Not yet recruiting Drug: Abemaciclib|Drug: MK-6482 Clear Cell Renal Cell Carcinoma Dana-Farber Cancer Institute|Eli Lilly and Company March 2021 Phase 1
NCT04169074 Not yet recruiting Drug: Abemaciclib|Drug: Abemaciclib plus nivolumab HNSCC University of Arizona January 1 2021 Phase 2
NCT04408924 Not yet recruiting Drug: Abemaciclib Metastatic Castration-Resistant Prostate Cancer Eli Lilly and Company December 18 2020 Phase 2
NCT04238819 Recruiting Drug: Abemaciclib|Drug: Irinotecan|Drug: Temozolomide Relapsed Solid Tumor|Refractory Solid Tumor Eli Lilly and Company November 9 2020 Phase 1
NCT04514159 Recruiting Drug: ZN-c5|Drug: Abemaciclib Breast Cancer Zeno Alpha Inc. November 2020 Phase 1

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1:

    Is your product S7158 LY2835219 “mesylate salt form”?

  • 回答:

    Our S7158 LY2835219 is mesylate salt form.

CDK Signaling Pathway Map

CDK Inhibitors with Unique Features

相关CDK产品

Tags: 购买Abemaciclib mesylate (LY2835219) | Abemaciclib mesylate (LY2835219)供应商 | 采购Abemaciclib mesylate (LY2835219) | Abemaciclib mesylate (LY2835219)价格 | Abemaciclib mesylate (LY2835219)生产 | 订购Abemaciclib mesylate (LY2835219) | Abemaciclib mesylate (LY2835219)代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID